跳至主要内容
临床试验/NCT01786616
NCT01786616已完成不适用

Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

Catholic University, Italy1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Peak Expiratory Flow (PEF) variability

研究概览

简要总结

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Mild to moderate asthma
  • Stable clinical conditions

排除标准

  • Current therapy with oral steroids
  • Exacerbations within the past 3 months

研究组 & 干预措施

Formoterol

12 mcg BID for four weeks

干预措施: Formoterol (Drug)

结局指标

主要结局

Peak Expiratory Flow (PEF) variability

时间窗: PEF has been monitorized during the 4-week treatment period

次要结局

  • Forced Expiratory Volume in 1 sec (FEV1) slope of the dose-response curve to salbutamol(At the end of the 4-week treatment period)

研究者

发起方
Catholic University, Italy
申办方类型
Other
责任方
Principal Investigator
主要研究者

Leonello Fuso

Researcher

Catholic University, Italy

研究点 (1)

Loading locations...

相似试验